ArticleBJC reports2026
A comprehensive analysis of lung cancer status changes over 10 years: results of Moroccan cohort.
Article in BJC reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAssessing long-term trends in lung cancer (LC) patients is challenging, particularly in regions with limited data. We present findings from a real-life Moroccan cohort.
methodsThis is a retrospective study that included patients diagnosed with LC as a primary malignancy between January 1st, 2013, and December 31st, 2022. Data were collected from one academic public hospital that, during this period, served as the referral centre for the middle and southern regions of Morocco. Patients', clinic, pathologic, and therapeutic characteristics were described. Analyses assessed temporal trends and stage-specific outcomes.
resultsOver the study period, LC rates were highest among men 88% (1206/1369), aged 55-60 years 22% (297/1369), who were current smokers 90% (1075/1206), while rates among women remained stable. Additionally, a rising trend was observed among NSCLC, particularly adenocarcinoma (56% (34/61) in 2013 vs. 65% (80/124) in 2022; p < 0.001), at the metastatic stage 72% (949/1320), whereas small-cell lung cancer (SCLC) remained under-represented at 4.4% (59/1337) in the overall population and 40% (59/146) in the lung neuroendocrine tumour (LNET) population, with stable incidence at 3% (2/70) in 2013 vs. 6% (10/163) in 2018 vs. 1.6% (3/190) in 2022; p = 0.8. Molecular testing was limited to EGFR in 6% of cases, ALK in 4.4%, and PD‑L1 in 5%. Systemic treatment was dominated by chemotherapy ±platinum, and only 7 patients received second‑line erlotinib. No improvement in survival rates was observed, and early mortality remained high 3-month rate: 0% for localised, 13.2% (95% CI, 9.9-17.2) for locally advanced, and 22.2% (95% CI, 19.6-25) for metastatic stage.
conclusionThis is the only, largest, retrospective, real-life cohort study including LC patients in the African region. The trend showed an overall rising LC incidence, a consistent predominance of advanced-stage diagnoses, high mortality rates, and a lack of survival improvement with limited therapeutic options over the studied decade. Strengthening efforts in early detection, tobacco-control, and expanding diagnostic capacity, while ensuring equitable access to biomarker testing and targeted treatments, remains central.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.